Literature DB >> 894339

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors.

V A Levin, D C Crafts, D M Norman, P B Hoffer, J P Spire, C B Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 894339     DOI： 10.3171/jns.1977.47.3.0329

Source DB:  PubMed          Journal:  J Neurosurg        ISSN： 0022-3085            Impact factor:   5.115


× No keyword cloud information.
  61 in total

1.  Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.

Authors:  Alexander Radbruch; Kira Lutz; Benedikt Wiestler; Philipp Bäumer; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2011-12-06       Impact factor: 12.300

2.  Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

Authors:  Victor A Levin; Surasak Phuphanich; W K Alfred Yung; Peter A Forsyth; Rolando Del Maestro; James R Perry; Gregory N Fuller; Mark Baillet
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

3.  CNS Anticancer Drug Discovery and Development Conference White Paper.

Authors:  Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 4.  New Directions in Anti-Angiogenic Therapy for Glioblastoma.

Authors:  Nancy Wang; Rakesh K Jain; Tracy T Batchelor
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

5.  Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.

Authors:  M D Prados; M S Edwards; J Rabbitt; K Lamborn; R L Davis; V A Levin
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 6.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

7.  Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia.

Authors:  V A Levin; M Chamberlain; P Silver; L Rodriguez; M Prados
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  The basis for current treatment recommendations for malignant gliomas.

Authors:  H A Fine
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

10.  Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas.

Authors:  K Jellinger; P Kothbauer; D Volc; R Vollmer; R Weiss
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.